Skip to main content
Kintor Pharmaceutical Limited logo

Kintor Pharmaceutical Limited — Investor Relations & Filings

Ticker · 9939 HKEX Manufacturing
Open in API
Filings indexed 312 across all filing types
Latest filing 2026-01-05 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 9939

About Kintor Pharmaceutical Limited

http://www.kintor.com.cn

Kintor Pharmaceutical Limited is a clinical-stage novel drug developer specializing in the research and development of innovative small molecule and biologic therapeutics. The company focuses on addressing substantial unmet medical needs within dermatology and oncology, with a particular emphasis on androgen receptor (AR)-related diseases. Kintor maintains a robust, multi-channel pipeline featuring proprietary technologies such as AR antagonists, AR-PROTACs, mTOR inhibitors, and the licensed ALK-1 antibody project. Key therapeutic targets include hair loss (AGA), acne, prostate cancer, and liver cancer. The company utilizes a global integrated R&D platform to develop combination therapies and has initiated commercialization efforts for cosmetic treatments derived from its pipeline.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for companies listed on the HKEX to report monthly movements in securities, share capital, and treasury shares. Since it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Share Issue' (which is for specific events) or 'Transaction in Own Shares' (which is for specific buybacks), it is best classified as a Regulatory Filing (RNS).
2026-01-05 English
(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR&#x3b; AND (2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR
Board/Management Information Classification · 1% confidence The document is an official announcement from Kintor Pharmaceutical Limited regarding the resignation of one non-executive director and the appointment of a new non-executive director. This content directly matches the definition for 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-12-11 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information Classification · 1% confidence The document is a formal list of directors and their roles and functions within the board committees of Kintor Pharmaceutical Limited. It identifies the members of the Board, categorizes them as Executive, Non-executive, and Independent Non-executive, and provides a table showing their committee memberships. This type of disclosure is standard corporate governance documentation regarding board structure and composition, which falls under the Governance Information category.
2025-12-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies to report monthly changes in their share capital, issued shares, and treasury shares. Since the document details a specific increase in issued shares due to a 'Placing/subscription' event, it falls under the category of share capital changes and new share issues.
2025-12-01 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 1% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It details a specific change in the company's issued share capital resulting from a subscription of new shares. This type of filing is a regulatory requirement for listed issuers to report changes in share capital, which falls under the 'Share Issue/Capital Change' category.
2025-11-21 English
COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement from Kintor Pharmaceutical Limited regarding the 'Completion of Subscription of New Shares'. It details the issuance and allotment of new shares, the use of proceeds, and the resulting change in the company's shareholding structure. This falls under the category of share issuance and capital changes, which is specifically defined as 'Share Issue/Capital Change' (SHA).
2025-11-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.